drugset / Trial / NCT03048448
Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
Non-randomizedParallel-groupOpen-labelOther
Summary
This study will characterize the pharmacokinetics (PK) of QAW039 after a single oral dose of QAW039 in patients with hepatic impairment compared to healthy matched control subjects.
Timeline
- Start
- 2017-05-31
- Primary completion
- 2019-04-22
- Completion
- 2019-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fevipiprant | Small molecule | 450 mg | Oral |
Indications
No indication recorded.